[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Charitable Union for the Research and Education of Peyronie's Disease\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100562615","ejaculatory-and-orgasmic-dysfunction-registry-100562615",false,"NCT06605469","Ejaculatory and Orgasmic Dysfunction Registry","Ejaculatory and Orgasmic Dysfunction Registry (Climax Registry)","Inclusion Criteria:\n\n* Men being treated for either ejaculatory and\u002For orgasmic dysfunction\n* For partners, inclusion is being a sexual partner of a man with ejaculatory and\u002For orgasmic dysfunction who is receiving treatment\n\nExclusion Criteria:\n\n* None",true,"ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","3 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the safety and efficacy of various therapies used to treat ejaculatory and\u002For orgasmic dysfunctions in men. The objective is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and\u002For orgasmic dysfunction.\n\nParticipants will submit questionnaires about their diagnosis and treatment efficacy and multiple time intervals.",[26,27,28,29,30,31,32],"Ejaculatory Dysfunction","Premature Ejaculation","Delayed Ejaculation","Anorgasmia","Anejaculation","Dysejaculation","Dysorgasmia",[34,35,36,37,38,39,40],"ejaculatory dysfunction","premature ejaculation","delayed ejaculation","anorgasmia","anejaculation","dysejaculation","dysorgasmia","RECRUITING","2025-02-12",{"date":44,"type":45},"2025-02-14","ACTUAL",{"date":47,"type":45},"2024-05-30",{"date":49,"type":21},"2029-05-31",{"name":51,"class":52},"Charitable Union for the Research and Education of Peyronie's Disease","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":53},"100566004","phase-4-delayed-dose-collagenase-clostridium-histolyticum-cch-protocol-for-men-with-peyronies-disease-100566004","NCT06649539","Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease","Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men With Peyronie's Disease","Inclusion Criteria:\n\n* Men with Peyronie's Disease\n* Older than 18 years old\n* Curvature ≥30 degrees\n* Ability to achieve an erection satisfactory for intercourse with or without phosphodiesterase-5 (PDE5) inhibitors\n* The patient exhibits a palpable plaque consistent with Peyronie's Disease\n* For partners, the only inclusion criteria is being willing to complete a questionnaire\n\nExclusion Criteria:\n\n* Prior surgical treatment on the penis (other than circumcision)\n* Prior treatment with CCH injections\n* Any contraindications to CCH - as determined by the PI",{"count":62,"type":21},40,"INTERVENTIONAL",[65],"PHASE4","Our team has previously demonstrated efficacy in performing a novel collagenase Clostridium histolyticum (CCH) injection protocol in men who previously failed to achieve a response to an initial 4 series of CCH.\n\nThe objective of the current study is to evaluate a protocol that incorporates limited in-office modeling for up to 4 series, followed by up to 2 additional salvage series to determine safety and efficacy compared to historical data.\n\nParticipants will receive up to 4 series of CCH injections using our previously published protocol, with mild in-office modeling. CCH injections are given on back-to back days, after which they are counseled to utilize Restorex and sildenafil daily, as instructed. Patients will undergo mild in-office modeling on day 2.\n\nThe sexual partners of study participants will also be invited to enroll in the study and will complete non-validated questionnaires detailing their level of support for the patient's treatment.",[68],"Peyronie Disease",[70,71,72,73,74,75],"collagenase clostridium histolyticum","curvature","Restorex","Xiaflex","traction","salvage",{"date":77,"type":45},"2025-02-13",{"date":79,"type":45},"2024-10-11",{"date":81,"type":21},"2029-10",{"name":51,"class":52},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":63,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":53},"100458043","efficacy-of-restorex-penile-traction-therapy-in-preserving-erectile-function-post-prostatectomy-100458043","NCT05244486","Efficacy of RestoreX Penile Traction Therapy In Preserving Erectile Function Post-Prostatectomy","Inclusion Criteria:\n\n* Undergoing bilateral nerve-sparing prostatectomy\n* \\>18 years old\n* Have a regular sexual partner for at least 6 months prior to study enrollment\n\nExclusion Criteria:\n\n* Requiring adjuvant radiation therapy or androgen deprivation \u002F androgen blockade post-operatively (by the time of enrollment)\n* Baseline severe erectile dysfunction as measured by the IIEF-EFD\n* Urethral complications from prostatectomy at the time of baseline visit including contrast extravasation, anastomotic dehiscence of vesicourethral anastomosis, need for re-doing of vesicourethral anastomosis intra-operatively","MALE",{"count":91,"type":21},200,[93],"NA","Evaluate the efficacy of the RestoreX penile traction device in preserving erectile function in men undergoing robotic-assisted prostatectomy. This study will evaluate men undergoing prostatectomy with bilateral nerve preservation and preserved baseline erectile function (moderate ED or better). The primary outcome will be changes in the IIEF-EFD scores between groups at 6 months. Secondary outcomes include differences in questionnaire outcomes at 3, 6, and 9 months.",[96],"Erectile Dysfunction Following Radical Prostatectomy",[98],"Penile traction therapy",{"date":77,"type":45},{"date":101,"type":45},"2022-03-12",{"date":103,"type":21},"2030-09-14",{"name":51,"class":52},""]